A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk
Launched by CARL WEINER, MD · Dec 12, 2007
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
After obtaining informed consent maternal demographics, vital signs, height, weight, medical history, pregnancy dating, dipstick for urine protein, previous lab results, nuchal translucency results and uterine artery Doppler results (if done) will be obtained. Blood for PP13 will be obtained at 7-13 weeks and optionally at 21-23 weeks. Hospitalization and delivery information will be obtained via a chart review for evidence of preeclampsia.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy, pregnant females
- • Singleton fetus at 7 0/7 to 13 6/7 weeks gestation
- Exclusion Criteria:
- • Multi-fetal pregnancy
- • Mental retardation
- • Known fetal anomaly or demise
- • BMI \> 35, serious medical condition
About Carl Weiner, Md
Dr. Carl Weiner, MD, is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical medicine and a focus on innovative therapeutic approaches, Dr. Weiner leads trials that explore novel interventions across various medical disciplines. His dedication to ethical research practices and patient safety ensures that all clinical trials are conducted with the highest standards of integrity and scientific rigor. Through collaboration with multidisciplinary teams, Dr. Weiner aims to translate research findings into effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Patients applied
Trial Officials
Carl Weiner, MD, MBA
Principal Investigator
University of Kansas Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials